1. Introduction {#sec1}
===============

Cardiogenic shock is characterized by a decline in cardiac function leading to a significant decrease in cardiac output and insufficient effective circulating blood volume, resulting in severe acute peripheral circulatory failure. The mortality rate from cardiogenic shock ranges from 50% to 80% \[[@B1]\]. The most common cause of cardiogenic shock is acute myocardial infarction (AMI), accounting for 80% of cases \[[@B2]\]. Approximately 50% of patients with AMI develop cardiogenic shock within six hours, and 75% develop it within 24 hours \[[@B3]\]. The use of digitalis drugs in the treatment of cardiogenic shock is controversial. When AMI is complicated by cardiogenic shock, myocardium in the ischemic area does not bind well with digitalis, thus increasing its toxicity, suggesting it should be avoided \[[@B2], [@B4]\].

The drug of choice for the treatment of cardiogenic shock is controversial. Milrinone has been shown to affect long-term mortality from cardiogenic shock \[[@B5]\], and levosimendan and adrenaline have been shown to have adverse side effects, which increase potential risks and incidence of adverse reactions \[[@B6], [@B7]\]. Dobutamine has been shown to adversely increase the heart rate \[[@B8], [@B9]\] and yet is recommended by others with half of clinicians using it for treatment of cardiogenic shock \[[@B10], [@B11]\]. The purpose of this study was to conduct a network meta-analysis on the clinical effects of medications used for the treatment of cardiogenic shock.

2. Materials and Methods {#sec2}
========================

2.1. Literature Review {#sec2.1}
----------------------

PubMed, EMBASE, Cochrane library, China National Knowledge Infrastructure (CNKI), Wanfang database, and Weipu database were searched for articles in Chinese or English using keywords Dopamine, Dobutamine, Epinephrine, Adrenaline, Norepinephrine, Noradrenaline, Milrinone, Natriuretic peptide, Recombinant human brain natriuretic peptide, Levosimendan, Cardiac shock, and Cardiogenic shock from January 1, 2009, to December 31, 2019.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Articles meeting the following criteria were included: (1) randomized clinical trials related to cardiogenic shock drug therapy, (2) diagnosis of cardiogenic shock as described in the 2014 Chinese Heart Failure Guide \[[@B12]\], (3) cardiogenic shock as the main treatment target in the study, and (4) outcome indicators being mortality and adverse reactions. Studies were excluded if they met the following criteria: (1) nonexperimental studies such as "reviews" and "case reports," (2) contained duplicate or low quality data or insufficient information and clinical data, (3) literature on traditional Chinese medicine and proprietary Chinese medicines for cardiogenic shock, and (4) animal experiments.

2.3. Data Extraction and Literature Quality Evaluation {#sec2.3}
------------------------------------------------------

Extracted data included the author, publication date, average age, research method, sample number, mortality rate, and incidence of adverse reactions. We evaluated bias based on evaluation criteria from the Cochrane Handbook for Systematic Reviews of Interventions including random sequence generation, whether to hide the allocation scheme, whether to use blind method, completeness of the outcome data, whether to selectively report the research results, and other sources of bias. According to the Cochrane Handbook evaluation standards, the literature is divided into 3 levels: low deviation: all meet the Cochrane Handbook evaluation standard; medium deviation: 1 undescribed Cochrane Handbook evaluation standard; high deviation: there are 2 or more items not described or 1 item does not meet the Cochrane Handbook evaluation standard.

2.4. Statistical Processing Methods {#sec2.4}
-----------------------------------

The network meta-analysis was conducted using ADDIS 1. 16. 8. Data were first tested for consistency using a node-split model. Where there was no statistical difference between direct and indirect comparison (*P* \> 0.05), the consistency model was used. Where there was a difference, an inconsistency model was used. The stability of the analysis results of the consistency model was tested using the inconsistency model. When the inconsistency factors included 0 and the inconsistency standard deviation included 1 and the consistency model results were more stable and reliable. Various analysis models were automatically iterated based on preset parameters, and the convergence of the iterative effect was judged by potential scale reduced factor (PSRF). When the PSRF value was close to or equal to 1 (1 ≤ PSRRF ≤ 1.05), the convergence is felt to be complete, and the model is believed to have good stability, rendering the analysis conclusion more reliable. Stata 14.0 was used to create the network diagram, and funnel diagrams were made to evaluate whether the included studies had publication bias.

3. Results {#sec3}
==========

3.1. Literature Review {#sec3.1}
----------------------

The included search terms identified 1387 articles. Using inclusion and exclusion criteria while evaluating the title, abstract, and full text of the literature, 28 articles were included, describing 1806 patients ([Figure 1](#fig1){ref-type="fig"}).

3.2. Basic Characteristics of the Literature {#sec3.2}
--------------------------------------------

The 28 clinical studies \[13--40\] included were all clinical trials using medications to treat cardiogenic shock. Seven (25%) of the 28 studies were conducted before 2015, and the remaining 21 (75%) studies were concentrated after 2015. The treatment cycle and dosage of the drugs in each group were basically the same, and the difference was not statistically significant ([Table 1](#tab1){ref-type="table"}).

3.3. Evaluation of Included Studies {#sec3.3}
-----------------------------------

Of the 28 studies \[[@B13]--[@B40]\], 7 (25%) clearly stated the method of randomization (random number table, admission order, etc.), 1 (3.5%) of the studies described the allocation concealment method, and none described the method of blinding; other sources of bias were unknown; the baseline patient characteristics of the studies were basically the same ([Table 2](#tab2){ref-type="table"}).

3.4. Network Meta-Analysis Results {#sec3.4}
----------------------------------

### 3.4.1. Network Diagram of Included Interventions {#sec3.4.1}

Each dot in the network diagram represents a drug, and a wired segment directly connected between the two points indicates a direct comparison between the two drugs. The larger the dot, the higher the frequency of study drugs being included in the reticulation analysis. The wider the line between the two dots, the higher the frequency of comparisons between drugs (Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}).

### 3.4.2. Node-Split Model Test and Convergence Judgment {#sec3.4.2}

Case fatality rate and incidence of adverse reactions were evaluated by node-split model method. Both *P* values were greater than 0.05, suggesting that there was no statistical inconsistency, supporting use of the consistency model for analysis. Both the consistency model analysis and the inconsistency model test of the network meta-analysis have PSRF values between 1 and 1.05, indicating that the convergence is good and the results are stable.

### 3.4.3. Network Meta-Analysis of Case Fatality Rate under the Consistency Model {#sec3.4.3}

Twenty of the 1199 studies \[[@B13]--[@B32]\] used case fatality rate as the outcome indicator, and these were included in a network meta-analysis. According to the ranking probability map of treatment measures (Rank 8 being the best and Rank 1 being the worst), the ability of drugs to reduce fatality was as follows: milrinone \> levosimendan \> norepinephrine \> recombinant human brain natriuretic peptide \> dobutamine \> epinephrine \> dopamine \> conventional treatment. Milrinone appeared to be the best treatment option to reduce the case fatality rate (with a probability of 44%), with levosimendan coming in second with a probability of 26%.

### 3.4.4. Network Meta-Analysis of the Incidence of Adverse Reactions under the Consistency Model {#sec3.4.4}

Eighteen of 1317 studies \[[@B24]--[@B40]\] used incidence of adverse reactions as the outcome indicator, and these were included in a network meta-analysis. According to the ranking probability map of treatment measures, the side effect profile from best to worst was as follows: milrinone \> recombinant human brain natriuretic peptide \> norepinephrine \> levosimendan \> conventional treatment \> epinephrine \> dobutamine \> dopamine. Milrinone appeared to be associated with the least amount of adverse reactions (with a probability of 55%), with recombinant human brain natriuretic peptide coming in second (with a probability of 32%).

### 3.4.5. Inconsistency Model Testing {#sec3.4.5}

The consistency model of the two outcome indicators was analyzed and inconsistency models were used to test the stability of the results. Results demonstrated that the inconsistency factors all included 0 and the inconsistency standard deviations all included 1. This means that the results of the consistency model were stable and reliable.

3.5. Publication Bias {#sec3.5}
---------------------

Funnel plots were created to identify small sample effects in the analysis. Funnel plots were created for the two outcome indicators for publication bias testing. Results demonstrated that the included studies were roughly symmetrically distributed on both sides of the funnel plot, and therefore the possibility of publication bias was felt to be small (Figures [4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}).

4. Discussion {#sec4}
=============

Cardiogenic shock is a serious disease that, if not treated expeditiously and appropriately at an early stage, can have a high risk of mortality. The pathological changes of cardiogenic shock usually include two parts: one is abnormal hemodynamics and the other is insufficient perfusion of surrounding tissues. The prognosis of patients is closely related to the degree of hemodynamic abnormalities, so the rapid correction of hemodynamic abnormalities in patients with cardiogenic shock is the key to treating cardiogenic shock \[[@B41]\]. In clinical treatment of cardiogenic shock, blood volume is usually appropriately supplemented, and positive inotropic drugs combined with vasoactive drugs are used. For example, calcium sensitizers, levosimendan, can be combined with troponin to enhance myocardial contractility, expand coronary arteries, and improve myocardial ischemia; *β*-receptor agonist dobutamine mainly stimulates myocardial *β*1 receptors and produces a positive inotropic effect. Phosphodiesterase inhibitors milrinone can inhibit phosphodiesterase III, increase the content of cyclic adenosine monophosphate in myocardial cells \[[@B42]\], exert positive inotropic effects, expand blood vessels, and improve hemodynamics. Recombinant human brain natriuretic peptide with peripheral vasodilators has similar biological activity with human-derived BNP, which can dilate blood vessels, reduce heart load, and inhibit ventricular remodeling. Although many medications have been investigated for the treatment of cardiogenic shock, a direct comparison of the effectiveness of these medications has not previously been conducted. We aimed to compare previously described medications for use in cardiogenic shock with the hope of identifying preferable medications that could be administered quickly in an emergency setting.

Our study identified milrinone as being the most effective medication for reducing fatality and having the best side effect profile. Milrinone can improve the patient\'s hemodynamic abnormalities and hypoperfusion status, thereby rapidly improving cardiac function and correcting heart failure, Therefore, the rapid and effective application of milrinone is of great significance to save patients\' lives. Levosimendan and recombinant human brain natriuretic peptide were the second most effective drugs in reducing the case fatality rate and adverse reactions. They have a positive effect on improving the clinical symptoms and prognosis of patients, and they can be used according to the patient\'s condition.

5. Limitations {#sec5}
==============

Limitations of this study include lesser quality of some studies included in the analysis, small sample sizes in others, and varied lengths of treatment across studies. These factors could affect the reliability of the reticulated meta-analysis. It is hoped that larger, multicenter randomized controlled trials will provide clinical data in the future to achieve a more comprehensive understanding and evaluation.

6. Conclusion {#sec6}
=============

In this paper, a reticular meta-analysis system is used to evaluate the difference in the efficacy of various drugs on different outcome indicators, which provides evidence-based evidence for clinical treatment, is conducive to more effective control of clinical symptoms and disease progression, and also for further clinical trials provided a reference. The analysis results showed that milrinone had the best effect in reducing the case fatality rate and the incidence of adverse reactions in patients with cardiogenic shock. Levosimendan and recombinant human brain natriuretic peptide were the second most effective drugs in reducing the case fatality rate and adverse reactions. Milrinone can improve the patient\'s hemodynamic abnormalities and hypoperfusion status and has the best clinical effect to reduce the patient\'s case fatality rate and incidence of adverse reactions. Therefore, milrinone is recommended as the clinically preferred drug for cardiogenic shock.
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![Network diagram of case fatality rate. Note: a, recombinant human brain natriuretic peptide; b, conventional treatment; c, dopamine; d, dobutamine; e, epinephrine; f, norepinephrine; g, milrinone; h, levosimendan.](JHE2020-8862256.002){#fig2}

![Network diagram of incidence of adverse reactions. Note: a, recombinant human brain natriuretic peptide; b, conventional treatment; c, dopamine; d, dobutamine; e, epinephrine; f, norepinephrine; g, milrinone; h, levosimendan.](JHE2020-8862256.003){#fig3}

![Funnel plot of case fatality rate for outcome indicator.](JHE2020-8862256.004){#fig4}

![Funnel plot of incidence of adverse reactions for outcome indicators.](JHE2020-8862256.005){#fig5}

###### 

Included literature information form.

  Include literature           Published time   Average age       Gender            Number of cases   Intervention measure                                            
  ---------------------------- ---------------- ----------------- ----------------- ----------------- ---------------------- ---- ---- ------------------------------ -----------------------------
  Levy et al. \[[@B13]\]       2011             66 ± 12           64 ± 10           21                9                      15   15   0.1 *μ*g/(kg·min)^e^           0.1 *μ*g/(kg·min)^f^
  Pan et al. \[[@B14]\]        2017             64.9 ± 12.6       64.1 ± 10.8       35                13                     25   23   0.005 mg/(kg·min)^a^           3--12 mg/(kg·min)^c^
  Bruno et al. \[[@B15]\]      2018             68 (55--79)       66 (55--77)       38                19                     27   30   0.02 *μ*g/(kg·min)^e^          0.02 *μ*g/(kg·min)^f^
  Zhou et al. \[[@B16]\]       2012             62.3 ± 1.8        60.2 ± 2.4        21                19                     20   20   60 *μ*g/kg^g^                  b
  Pang and Zhao \[[@B17]\]     2011             60.2 ± 9.8        60.2 ± 9.8        28                22                     25   25   75 *μ*g/kg^g^                  NA^d^
  Li \[[@B18]\]                2016             68.4 ± 11.3       70.8 ± 10.7       23                17                     20   20   12 *μ*g/kg^h^                  b
  Chen \[[@B19]\]              2018             58.22 ± 5.03      60.05 ± 4.85      43                19                     30   32   ^f^ 0.05--0.19 *μ*g/(kg·min)   5--20 *μ*g/(kg·min)^c^
  Xiong et al. \[[@B20]\]      2016             78.76 ± 7.17      76.77 ± 6.41      40                20                     30   30   ^f^ 0.05--2.0 *μ*g/(kg·min)    5--20 *μ*g/(kg·min)^c^
  Tsagalou et al. \[[@B21]\]   2009             70 ± 9            69 ± 11           22                3                      12   13   6 *μ*g/(kg·min)^h^             10 *μ*g/(kg·min)^d^
  Yang \[[@B22]\]              2015             66.7 ± 6.5        65.3 ± 6.2        31                15                     23   23   6 *μ*g/kg^h^                   2.5 *μ*g/(kg·min)^d^
  Zhang and Xiao \[[@B23]\]    2010             65.9 ± 0.2        65.9 ± 0.2        48                40                     44   44   2--10 *μ*g/(kg·min)^c^         b
  Lewis et al. \[[@B24]\]      2019             72.5 (59--81)     75 (67--83)       51                49                     50   50   0.25 *μ*g/(kg·min)^g^          2.5 *μ*g/(kg·min)^d^
  Pan et al. \[[@B25]\]        2018             68.36 ± 10.78     68.78 ± 10.72     46                34                     40   40   12 *μ*g/kg^h^                  b
  Shen \[[@B26]\]              2017             46.0 ± 6.1        46.6 ± 6.3        26                22                     24   24   12 *μ*g/kg^h^                  ^f^ 0.01--0.1 *μ*g/(kg·min)
  Tan \[[@B27]\]               2016             56.75 ± 12.17     58.37 ± 13.24     45                35                     30   50   ^f^ 0.05--0.19 *μ*g/(kg·min)   10--20 *μ*g/(kg·min)^c^
  Wang et al. \[[@B28]\]       2011             57 ± 13           57 ± 13           31                20                     25   26   0.19 *μ*g/(kg·min)^f^          20 *μ*g/(kg·min)^c^
  He et al. \[[@B29]\]         2014             63.52 ± 1.12      63.52 ± 1.12      26                21                     25   22   ^f^ 0.05--0.19 *μ*g/(kg·min)   10--20 *μ*g/(kg·min)^c^
  Li et al. \[[@B30]\]         2015             58.6 ± 10.1       58.6 ± 10.1       33                27                     30   30   ^f^ 0.05--0.5 *μ*g/(kg·min)    1--20 *μ*g/(kg·min)^c^
  Zhou and Zhou \[[@B31]\]     2019             67.96 + 5.92      68.13 + 5.38      93                29                     64   58   ^f^ 0.05--2.00 *μ*g/(kg·min)   10--20 *μ*g/(kg·min)^c^
  Li \[[@B32]\]                2019             69.4 ± 8.7        68.1 ± 8.2        55                31                     43   43   1.5 *μ*g/kg^a^                 b
  Lewis et al. \[[@B33]\]      2015             73                73                50                50                     50   50   NA^g^                          NA^d^
  Su \[[@B34]\]                2019             58.5 ± 3.3        59.5 ± 3.5        38                30                     34   34   ^f^ 0.1--0.5 *μ*g/(kg·min)     ^d^ 4.0--5.5 *μ*g/(kg·min)
  Guo et al. \[[@B35]\]        2017             62.75 ± 2.52      62.75 ± 2.52      37                23                     30   30   12 *μ*g/(kg·min)^h^            2 *μ*g/(kg·min)^d^
  Peng et al. \[[@B36]\]       2015             59.7 ± 1.4        58.6 ± 1.2        55                53                     54   54   12 *μ*g/kg^h^                  2.5 *μ*g/(kg·min)^d^
  Huang et al. \[[@B37]\]      2018             67.2 ± 3.8        68.3 ± 4.2        37                29                     33   33   12 *μ*g/kg^h^                  2.5 *μ*g/(kg·min)^d^
  Huang et al. \[[@B38]\]      2018             67.65 ± 4.69      67.59 + 4.75      55                39                     47   47   12 *μ*g/(kg·min)^h^            2 *μ*g/(kg·min)^d^
  Chen et al. \[[@B39]\]       2019             68\. 05 ± 6. 73   68\. 46 ± 6. 47   25                15                     20   20   6 *μ*g/kg^h^                   25 *μ*g/kg^g^
  Yang and Sun \[[@B40]\]      2018             61.21 ± 2.14      61.25 ± 2.44      26                24                     25   25   12 *μ*g/(kg·min)^h^            2 *μ*g/(kg·min)^d^

*Note*. E is the treatment group; C is the control group. ^a^Recombinant human brain natriuretic peptide; ^b^conventional treatment. ^c^dopamine; ^d^dobutamine; ^e^epinephrine; ^f^norepinephrine; ^g^milrinone; ^h^levosimendan;

###### 

Literature bias risk assessment results.

  Include literature           Stochastic method     Allocation concealment   Blind method   Outcome data integrity            Selective report results   Other sources of bias
  ---------------------------- --------------------- ------------------------ -------------- --------------------------------- -------------------------- -----------------------
  Levy et al. \[[@B13]\]       Randomize the code    Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Pan et al. \[[@B14]\]        Unclear               Label                    Unclear        Lost to follow-up, ITT analysis   No                         Unclear
  Bruno et al. \[[@B15]\]      Unclear               Unclear                  Unclear        Lost to follow-up, ITT analysis   No                         Unclear
  Zhou et al. \[[@B16]\]       Admission order       Unclear                  Unclear        Lost to follow-up, ITT analysis   No                         Unclear
  Pang and Zhao \[[@B17]\]     Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Li \[[@B18]\]                Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Chen \[[@B19]\]              Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Xiong et al. \[[@B20]\]      Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Tsagalou et al. \[[@B21]\]   Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Yang \[[@B22]\]              Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Zhang and Xiao \[[@B23]\]    Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Lewis et al. \[[@B24]\]      Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Pan et al. \[[@B25]\]        Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Shen \[[@B26]\]              Unclear               Unclear                  Unclear        Lost to follow-up, ITT analysis   No                         Unclear
  Tan \[[@B27]\]               Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Wang et al. \[[@B28]\]       Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  He et al. \[[@B29]\]         Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Li et al. \[[@B30]\]         Unclear               Unclear                  Unclear        Lost to follow-up, ITT analysis   No                         Unclear
  Zhou and Zhou \[[@B31]\]     Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Li \[[@B32]\]                Random number table   Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Lewis et al. \[[@B33]\]      Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Su \[[@B34]\]                Random grouping       Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Guo et al. \[[@B35]\]        Random number         Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Peng et al. \[[@B36]\]       Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Huang et al. \[[@B37]\]      Random number table   Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Huang et al. \[[@B38]\]      Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Chen et al. \[[@B39]\]       Random number table   Unclear                  Unclear        Not lost to follow-up             No                         Unclear
  Yang and Sun \[[@B40]\]      Unclear               Unclear                  Unclear        Not lost to follow-up             No                         Unclear
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